KB801

Biologic

KKrystal Biotech, Inc.

KB801 is one of 24 biologic programs targeting Keratitis. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

KeratitisActive, not recruiting

KeratitisPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

55 competitors in Keratitis

#DrugCompanyPhaseTrials

Avelox

Neoral

Rayos

Decadron

AAspen Global Incorporated

Levaquin

Deltasone

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Acthar

1 8

OXERVATE

DDompé Farmaceutici S.p.A

Approved

1 9

Cenegermin

DDompé Farmaceutici S.p.A

Approved

1 10

Oxervate

DDompé Farmaceutici S.p.A

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1/2Recruiting

Keratitis

NCT06999733

Clinical

Trials by Indication[1]

Keratitis1 trial

A Study Comparing KB801 Verse Placebo in Patients With Stage 2 or 3 Neurotrophic Keratitis

Recruiting·KKrystal Biotech, Inc.·Phase 1/2·NCT06999733·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for KB801. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — KB801 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for KB801. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Krystal Biotech, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Company: KKrystal Biotech, Inc.

KB801

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Keratitis1 trial

References

Drug Info

Quick Facts

Related News